Vanda Pharmaceuticals is a commercial-stage biopharmaceutical company whose portfolio includes Fanapt (schizophrenia), HETLIOZ, and PONVORY, alongside a pipeline centered on tradipitant (motion sickness) and the investigational therapy imsidolimab. Because the company is loss-making, analysts anchor their price targets to revenue potential and pipeline milestones rather than current earnings.
For this analysis, four current, attributable analyst price targets were reviewed. H.C. Wainwright reiterated a $20 target in October 2026, while Oppenheimer initiated coverage with an Outperform rating and a $10 target in September 2026. B. Riley Securities set a $12 target in August 2026, and Cantor Fitzgerald reiterated a $11 target the same month. The arithmetic mean of these four is $13.25, rounded to a clean $13 central target, with a range of roughly $10 to $20.
For broader context, the full analyst population has been even wider. Truist Financial previously carried an $18 target in May 2026 before its lead analyst moved coverage to Oppenheimer, and Jefferies held a more cautious $7.50 target (Hold) dating to late 2025. Bullish firms emphasize BYSANTI's potential and the firm's commercial positioning in neuropsychiatry, while cautious analysts point to execution risk and the lack of near-term profitability. This divergence is why the mean sits far below the highest individual target.
As of the most recent close, VNDA traded at $4.09, near the bottom of its 52-week range of roughly $4.00 to $9.94. Reaching $13 would require the stock to more than triple, a move that is very large by any standard. The company's fundamentals explain the gap: trailing-twelve-month revenue is about $215.7 million, but the business is unprofitable, with a trailing net loss near $275 million and negative operating margins. The company holds about $170 million in cash against modest debt of roughly $23 million.
A path toward the target would almost certainly require a re-rating driven by the successful commercialization of new products — principally BYSANTI and the tradipitant-based motion sickness therapy — rather than by existing sales alone. Management has described meaningful revenue ambition around the psychiatry portfolio, but those projections depend on converting Fanapt prescriptions to BYSANTI and achieving pricing and volume gains that have not yet been demonstrated.
VNDA's market structure is currently bearish. The price sits below both its 50-day simple moving average (near $5.01) and its 200-day moving average (near $6.38), and it has recently tested the $4.00 area, which now represents a key support level and psychological floor. The 52-week high of about $9.94 marks a distant resistance level, with nearer resistance around the $5.00 psychological mark and the 50-day moving average. A durable move toward $13 would require first reclaiming these moving averages and breaking a long-term downtrend.
Analyst price targets for VNDA generally reflect a roughly 12-month research horizon, though individual firms may apply different assumptions. The most important near-term items are the next quarterly earnings report and guidance, updates on the BYSANTI launch and tradipitant commercialization, prescription trends for Fanapt, and any regulatory decisions on pipeline programs. Investors should also watch for analyst target revisions, given how quickly the range has shifted over the past year, and for any evidence that new-product revenue is materializing as modeled.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like VNDA, such tools can help traders surface opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Traders can use these signals to stay ahead of momentum changes and refine their market outlook.
Whether VNDA can reach $13 depends almost entirely on whether its pipeline and new-product launches generate the revenue that bullish analysts are modeling. The $13 central target — the mean of four current analyst targets ranging from $10 to $20 — implies a very large move from the $4.09 share price and sits far above cautious views near $7.50. The strongest supports are the BYSANTI opportunity, growing Fanapt prescriptions, and a cash position that can fund the near term, while the principal obstacles are sustained losses, execution risk, and a downtrend that has pushed the stock toward its 52-week low. The target is a possibility rooted in genuine analyst optimism, not a forecast or guarantee, and it will be validated or undermined by the next several quarters of launch data and earnings.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with IVF. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then IVF could also see price increases.
| Ticker / NAME | Correlation To VNDA | 1D Price Change % | ||
|---|---|---|---|---|
| VNDA | 100% | +1.00% | ||
| IVF - VNDA | 40% Loosely correlated | -0.97% | ||
| ARVN - VNDA | 38% Loosely correlated | +2.18% | ||
| EDIT - VNDA | 37% Loosely correlated | -0.80% | ||
| DYN - VNDA | 37% Loosely correlated | -1.87% | ||
| COGT - VNDA | 37% Loosely correlated | -0.38% | ||
More | ||||